This HTML5 document contains 86 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00782/identifier/drugbank/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00782/identifier/iuphar/
dctermshttp://purl.org/dc/terms/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00782/identifier/guide-to-pharmacology/
n8http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n6http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00782/identifier/national-drug-code-directory/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n17http://linked.opendata.cz/resource/drugbank/mixture/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00782/identifier/chemspider/
n18http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB00782/identifier/pharmgkb/
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00782/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
n12http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00782/identifier/kegg-compound/
n23http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00782/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00782/identifier/pubchem-substance/
n27http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00782
rdf:type
n3:Drug
n3:description
A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. [PubChem]
n3:dosage
n19:271B6002-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
For the treatment of enuresis. It has also been used for hyperhidrosis, and cramps or spasms of the stomach, intestines or bladder.
n3:manufacturer
n6:271B5FF6-363D-11E5-9242-09173F13E4C5 n6:271B5FF9-363D-11E5-9242-09173F13E4C5 n6:271B5FF7-363D-11E5-9242-09173F13E4C5 n6:271B5FF8-363D-11E5-9242-09173F13E4C5 n6:271B5FFA-363D-11E5-9242-09173F13E4C5 n6:271B5FFB-363D-11E5-9242-09173F13E4C5 n6:271B5FF4-363D-11E5-9242-09173F13E4C5 n6:271B5FF5-363D-11E5-9242-09173F13E4C5 n6:271B5FF3-363D-11E5-9242-09173F13E4C5 n6:271B5FFE-363D-11E5-9242-09173F13E4C5 n6:271B5FFC-363D-11E5-9242-09173F13E4C5 n6:271B5FFD-363D-11E5-9242-09173F13E4C5
owl:sameAs
n16:DB00782 n18:DB00782
dcterms:title
Propantheline
adms:identifier
n10:Propantheline n11:PA164746224 n20:4765 n21:DB00782 n24:4934 n25:46507187 n26:0054-4721-25 n28:329 n29:C07506 n30:329
n3:mechanismOfAction
Action is achieved via a dual mechanism: (1) a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites and (2) a direct effect upon smooth muscle (musculotropic).
n3:packager
n6:271B5FF2-363D-11E5-9242-09173F13E4C5 n6:271B5FF0-363D-11E5-9242-09173F13E4C5 n6:271B5FF1-363D-11E5-9242-09173F13E4C5 n6:271B5FEE-363D-11E5-9242-09173F13E4C5 n6:271B5FEF-363D-11E5-9242-09173F13E4C5 n6:271B5FEC-363D-11E5-9242-09173F13E4C5 n6:271B5FED-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Approximately 70% of the dose is excreted in the urine, mostly as metabolites.
n3:synonym
SID11111683 Propanthéline, bromure de Propantelina, bromuro de Propantheline Propanthelin bromid SID90340675 Propanthelini Bromidum SID11112101 Propantelina bromuro
n7:hasAHFSCode
n8:12-08-08
n3:mixture
n17:271B5FEB-363D-11E5-9242-09173F13E4C5
n3:salt
n12:hasConcept
n13:M0017746
foaf:page
n23:propantheline.html
n3:IUPAC-Name
n4:271B6007-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B600D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B600C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6009-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B600A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B600B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6005-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6003-363D-11E5-9242-09173F13E4C5 n4:271B6006-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6004-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n27:A03AB05
n3:H-Bond-Acceptor-Count
n4:271B6013-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6014-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B600E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B600F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6011-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6010-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6012-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
298-50-0
n3:category
n3:containedIn
n5:271B6000-363D-11E5-9242-09173F13E4C5 n5:271B6001-363D-11E5-9242-09173F13E4C5 n5:271B5FFF-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B6019-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B601B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B601C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6018-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6017-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B601A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6008-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6015-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6016-363D-11E5-9242-09173F13E4C5